Lacosamida Hikma (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilizes the inactive state of the channels, limiting repetitive neuronal firing and decreasing neuronal hyperexcitability, which helps prevent the initiation and spread of seizure activity.

The dose of Lacosamida Hikma is individualized by the prescribing clinician based on the patient’s age, weight, renal and hepatic function, and response to therapy. The healthcare professional determines the appropriate infusion rate and total daily amount according to established clinical guidelines.

Lacosamide is classified as Pregnancy Category B, indicating that animal studies have not shown fetal risk, but there are limited human data. It may be used during pregnancy only if the potential benefit justifies the potential risk. Limited data are available for breastfeeding; caution is advised and a risk‑benefit assessment should be performed.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

Lacosamide’s mechanism—enhancing slow sodium‑channel inactivation—differs from agents such as carbamazepine, which target fast inactivation, and levetiracetam, which binds SV2A. Clinically, lacosamide is often well‑tolerated with a lower incidence of cognitive side effects, but it requires intravenous administration and careful cardiac monitoring, whereas many oral alternatives do not.

Lacosamida Hikma should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product must be transported, maintain the cold‑chain using validated insulated containers and temperature monitors.

The medication is given as an intravenous infusion. The vial is typically diluted with compatible IV fluid and infused over 15 minutes, although the exact rate is determined by the prescriber. Administration should occur under clinical supervision with monitoring of vital signs and cardiac rhythm.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation or atrial fibrillation, severe skin reactions like Stevens‑Johnson syndrome, and the potential for suicidal thoughts. Patients should be monitored for ECG changes, skin eruptions, and mood alterations throughout therapy.

Lacosamida Hikma is contraindicated in individuals with known hypersensitivity to lacosamide or any excipients in the formulation. It should also be avoided in patients with severe cardiac conduction disorders (e.g., second‑ or third‑degree AV block) unless under strict cardiac monitoring, and in those taking medications that present major interaction risks without appropriate supervision.